Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children

Pediatr Blood Cancer. 2019 Aug;66(8):e27803. doi: 10.1002/pbc.27803. Epub 2019 May 7.

Abstract

Classic Hodgkin lymphoma post-transplant lymphoproliferative disorder (HL-PTLD) has been rarely reported in children, with limited data available to guide treatment decisions. We report a retrospective review of five children diagnosed with classic HL-PTLD following solid organ transplant between 2007 and 2013 at Stanford University. Patients were treated with Stanford V chemotherapy and involved field radiation therapy. With a median follow-up of 7.2 years (range, 4.7-10.5 years) since diagnosis, all patients remain in remission from HL-PTLD and free from graft failure. In this series, combined modality therapy with risk-adapted chemotherapy and radiation therapy was a successful strategy for the treatment of classic HL-PTLD.

Keywords: HL-PTLD; pediatrics; radiation therapy; solid organ transplant.

MeSH terms

  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Hodgkin Disease / etiology
  • Hodgkin Disease / pathology
  • Hodgkin Disease / therapy*
  • Humans
  • Infant
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / pathology
  • Lymphoproliferative Disorders / therapy*
  • Male
  • Organ Transplantation / adverse effects*
  • Postoperative Complications / etiology
  • Postoperative Complications / pathology
  • Postoperative Complications / therapy*
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome